University of Alabama at Birmingham Hospital, Birmingham, Alabama, United States
This is a Phase 1, multicenter, open-label study of CC-98633, BCMA-Targeted NEX-T Chimeric
Antigen Receptor (CAR) T Cells, in subjects with relapsed and/or refractory multiple myeloma.
The study will consist of 2 parts: dose-escalation (Part A) and dose-expansion (Part B). The
dose-escalation part (Part A) of the study is to evaluate the safety and tolerability of
increasing dose levels of CC-98633 to establish a recommended Phase 2 dose (RP2D); and the
dose-expansion part (Part B) of the study is to further evaluate the safety,
pharmacokinetics/pharmacodynamics, and efficacy of CC-98633 at the RP2D.